But behind the headlines and hashtags lies a disturbing trend that deserves urgent attention: the rise of compounded GLP-1s ...

The U.S. Food and Drug Administration (FDA) already declared that shortages of popular GLP-1 medications have ended, CNN reported. Those medications include semaglutide (Ozempic and Wegovy) and ...

A GROWING number of slimmers are trying to squeeze extra jabs out of empty Mounjaro pens in a risky bid to cut costs. The ...

Cirius Therapeutics, Inc.,  developing innovative therapies for patients suffering from diseases caused by insulin resistance, including obesity/overweight and type 2 diabetes (T2D), today announced ...

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli Lilly's diabetes and obesity drug tirzepatide. The US ...

Regulators in the United Kingdom issued guidance on Thursday, warning that weight loss and diabetes medications may weaken ...

Welldoc®, a leader in AI-powered digital health innovation, today announced it will power the newly launched Lilly Healthtm Personalized Health & Medicine Platform* (Lilly Health app) with its ...

Lilly has filed to lend its support to the FDA in a lawsuit filed against the agency by the OFA and FarmaKeio Custom Compounding, which are challenging a decision to remove tirzepatide from the ...

Weight-loss drugs like Ozempic and Wegovy are used by more than 15 million adults in the U.S., or 4.5% of the population.

On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight ...